dusigitumab (MEDI-573) / AstraZeneca  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dusigitumab (MEDI-573) / AstraZeneca
NCT01340040: Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects

Completed
1
10
Japan
MEDI-573
AstraZeneca, MedImmune LLC
Cancer, Advanced Solid Malignancies
04/12
05/12
NCT00816361: A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors

Checkmark MEDI-573 in adult patients with solid tumors
Jun 2012 - Jun 2012: MEDI-573 in adult patients with solid tumors
Completed
1
43
US
MEDI-573
MedImmune LLC
Cancer
09/12
09/12

Download Options